Ascendis Pharma A/S - ADR

Ascendis Pharma A/S - ADR

ASND

Get informed when a big investor buys or sells

+ Follow
Market Cap$14.15B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Ascendis Pharma A/S - ADRAscendis Pharma A/S - ADR16.7-53%14.20.3
$315.47

Target Price by Analysts

38.4% upsideAscendis Pharma A/S Target Price DetailsTarget Price
$158.03

Current Fair Value

30.7% downside

Overvalued by 30.7% based on the discounted cash flow analysis.

Share Statistics

Market cap$14.15 Billion
Enterprise Value$13.79 Billion
Dividend Yield$- (-)
Earnings per Share$-3.62
Beta0.37
Outstanding Shares64,344,993

Return

Return on Equity52.64%ROE
Return on Assets33.08%
Return on Invested Capital2.26%

Valuation & Multiples

P/E Ratio16.73P/E Ratio
PEG-2.61PEG
Price to Sales14.24Price to Sales
Price to Book Ratio10.36Price to Book Ratio
Enterprise Value to Revenue13.08
Enterprise Value to EBIT335.77
Enterprise Value to Net Income18
Total Debt to Enterprise0.03
Debt to Equity0.32Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
August 13, 2026
EPS Estimate
$1.71
Average shareholder expectation
Revenue Estimate
$376.75 M
Average shareholder expectation

Next Earnings Call

Expected Date
November 11, 2026
EPS Estimate
$1.13
Average shareholder expectation
Revenue Estimate
$473.53 M
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.3575▲ 19.47%
Total Calls571,700▼ 55.05%
Total Puts204,400▼ 1.30%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %104.00%▲ 15.29%
Total Invested$17.85B▲ 42.73%
Investors Holding334▲ 43.00%

ESG Score

No data

About Ascendis Pharma A/S

CEO: Jan Moeller Mikkelsen